CARLSBAD, Calif. and BERLIN, Aug. 28, 2017 /PRNewswire/ -- The 23rd annual BIO-Europe® 2017 global life science partnering event will be held in Berlin, November 6–8, 2017, in partnership with Berlin Partner and Berlin-Brandenburg HealthCapital. The event is expected to bring together over 3,900 executives from 2,000+ life science companies spanning an estimated 60+ countries to engage in one-to-one partnering.
Berlin is a vital biopharma and health sector with many new digital health startups. Almost 600 life science businesses are based in Berlin, including more than 240 biotech, 300 medical technology and 30 pharmaceutical companies like Bayer, Pfizer and Sanofi.
"Berlin is not only a popular tourist city but is a leading location for biopharmaceutical innovation," said Dr. Kai Uwe Bindseil, Cluster Manager for Healthcare Industries in Berlin-Brandenburg – HealthCapital. "It's a central hub for governmental and political decisionmakers and Federal Government institutions, as well as patient groups and associations, which together form a cohesive community to shape the business and future of human health."
"We are pleased to partner with Berlin Partner to bring BIO-Europe to Berlin," said Anna Chrisman, Group Managing Director, EBD Group. "Berlin-Brandenburg is one of the leading life sciences and healthcare industries centers in the world, and is the perfect setting for the dealmaking and discovery that takes place at BIO-Europe to further global drug development."
BIO-Europe is Europe's largest partnering conference serving the global biotechnology industry. The event is a draw for executives in the life sciences who will gain direct access to service and manufacturing partners, innovative assets, and ideas from biotech companies ranging from very early stage to large, established companies. The event is also a critical business strategy for biotech companies to meet with pharma executives and investors to propel their drug development commercialization goals.
BIO-Europe 2016 broke records for number of delegates and number of one-to-one partnering meetings which reached 20,833, an all-time high and up 9% from 2015. CEOs and decision makers from 1,982 companies and 63 countries discussed asset deals and strategic collaborations. There were 4,734 licensing opportunities on offer, 153 company presentations and 97 exhibitors.
Register for BIO-Europe 2017 before August 31, 2017 and save EUR 200 off the regular registration rate.
Read more on Berlin's supercluster here. For news and interviews with executives and thought leaders in the life science industry, go to EBD Group's Partnering Insight.
Additional links and information:
Follow BIO-Europe 2017 on Twitter: @EBDGroup (hashtag: #BIOEUROPE).
About EBD Group
EBD Group is the leading partnering firm for the global life science industry.
EBD Group's conferences are run with the support of leading corporations and international trade associations and include:
- BIO-Europe® and BIO-Europe Spring®
- BioPharm America™
- Biotech Showcase™
- Digital Medicine & Medtech Showcase
- BioEquity Europe
- ChinaBio® Partnering Forum
- Cell & Gene Exchange
EBD Group has offices in the USA and Europe.
For more information please visit www.ebdgroup.com.
Contact:
Erin Righetti
EBD Group
+1 760 930 0500
[email protected]
SOURCE EBD Group
Share this article